Answers are grounded in this paper and cite their sources.
Our laboratory and others have developed protocols to generate glucose-responsive stem cell-derived β cells in vitro. The cells resulting from these protocols could supplement or replace the use of human cadaveric islets for cell-based therapy for diabetes. The combination of an unlimited supply of pluripotent stem cell-derived β cells and gene-editing approaches will facilitate numerous in vitro studies not possible with cadaveric islets. Here, we describe a protocol for fluorescent labeling and isolation of stem cell-derived β cells. This purification of SC-β cells is based on intracellular zinc content and is a simple method to complement other approaches for generating and assaying these cells.
No takes yet. Share an insight, caveat, or question.
Davis et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: